Which generation of targeted drug is sotoracib (AMG510) produced in Ziska, Bangladesh?

Sotoracib (AMG510) is a third-generation targeted drug indicated for the treatment of adults (who have received at least one systemic therapy) with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer(NSCLC).

Sotoracib is the first targeted drug to treat KRAS G12C mutation and has a significant effect in the treatment of lung cancer. Sotoraxibu produced by Zisika Pharmaceuticals in Bangladesh has been launched and has government approval. The quality of the drug is guaranteed.

Usual adult dose for non-small cell lung cancer: 960 mg orally once daily Treatment duration until disease progression or unacceptable toxicity. If hepatotoxicity occurs during treatment, symptomatic grade 2AST or ALT or 3-4< grade AST or ALT, the drug should be discontinued until recovery to grade 1 or lower or baseline, and treatment should be resumed at the next lower dose level. The first dose is reduced to 480 mg PO once daily. The second dose is reduced to 240 mg PO once daily. AST or ALT3 times higher than the upper limit of normal (3 timesULN ), total bilirubin is 2 times ULN, and there is no alternative reason, the drug should be permanently discontinued. If adverse reactions occur, a maximum of 2 dose reductions are allowed and the drug should be discontinued if the patient cannot tolerate the lowest dose of 240 mg orally once daily. Dose reduction for adverse reactions:First dose reduction: 480mg orally, once daily. Second dose reduction: 240mg PO once daily. Bangladesh Ziska Pharmaceuticals is located in2022 It will be launched in Bangladesh in December December . The retail price of 120mg56 capsules 3 is around 1,000. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0